Simon F. Lacey

Simon F. Lacey

Auto-generated profile, based on publicly available information

Simon F. Lacey

Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DODonald M. O’rourke
Donald M. O’rourke
MNMacLean Pancoast Nasrallah
MacLean Pancoast Nasrallah
ADArati Desai
Arati Desai
Jan Joseph MelenhorstJan Joseph Melenhorst
Jan Joseph Melenhorst
KMKeith Mansfield
Keith Mansfield
MMMarcela V. Maus
Marcela V. Maus
A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.

4 September 2020 in Science
Verified
Journal Article
Open access
PDF file
DMDivij Mathew
Divij Mathew
JGJosephine R. Giles
Josephine R. Giles
ABAmy E. Baxter
Amy E. Baxter
DODerek A. Oldridge
Derek A. Oldridge
AGAllison R. Greenplate
Allison R. Greenplate
AVAshley N. Vanderbeck
Ashley N. Vanderbeck
Immune profiling of COVID-19 patients: Coronavirus disease 2019 (COVID-19) has affected millions of people globally, yet how the human immune system responds to and influences COVID-19 severity remains unclear. Mathew et al. present a comprehensive atlas of immune modulation associated with COVID-19. They performed high-dimensional flow cytometry of hospitalized COVID-19 patients and found three prominent and distinct immunotypes that are related to disease severity and clinical parameters. Arunachalam et al. report a systems biology approach to assess the immune system of COVID-19 patients with mild-to-severe disease. These studies provide a compendium of immune cell information and roadmaps for potential therapeutic interventions. Science , this issue p. eabc8511 , p. 1210

28 February 2020 in Science
Verified
Journal Article
Closed access
PDF file
ESEdward A. Stadtmauer
Edward A. Stadtmauer
JFJoseph A. Fraietta
Joseph A. Fraietta
MDMegan M. Davis
Megan M. Davis
ACAdam Cohen
Adam Cohen
KWKristy L. Weber
Kristy L. Weber
CJCarl H. June
Carl H. June
CRISPR takes first steps in humans: CRISPR-Cas9 is a revolutionary gene-editing technology that offers the potential to treat diseases such as cancer, but the effects of CRISPR in patients are currently unknown. Stadtmauer et al. report a phase 1 clinical trial to assess the safety and feasibility of CRISPR-Cas9 gene editing in three patients with advanced cancer (see the Perspective by Hamilton and Doudna). They removed immune cells called T lymphocytes from patients and used CRISPR-Cas9 to disrupt three genes ( TRAC, TRBC , and PDCD1 ) with the goal of improving antitumor immunity. A cancer-targeting transgene, NY-ESO-1, was also introduced to recognize tumors. The engineered cells were administered to patients and were well tolerated, with durable engraftment observed for the study duration. These encouraging observations pave the way for future trials to study CRISPR-engineered cancer immunotherapies. Science , this issue p. eaba7365 ; see also p. 976

29 April 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ACAdam Cohen
Adam Cohen
AGAlfred L. Garfall
Alfred L. Garfall
ESEdward A. Stadtmauer
Edward A. Stadtmauer
JMJ. Joseph Melenhorst
J. Joseph Melenhorst
SLSimon F. Lacey
Simon F. Lacey
MMMichael C. Milone
Michael C. Milone
Background: Chimeric antigen receptor (CAR) T cells are a promising therapy for hematologic malignancies. B-cell maturation antigen (BCMA) is a rational target in multiple myeloma (MM). Methods: We conducted a phase I study of autologous T cells lentivirally-transduced with a fully-human, BCMA-specific CAR containing CD3ζ and 4-1BB signaling domains (CART-BCMA), in subjects with relapsed/refractory MM. Twenty-five subjects were treated in 3 cohorts: 1) 1-5 x 108 CART-BCMA cells alone; 2) Cyclophosphamide (Cy) 1.5 g/m2 + 1-5 x 107 CART-BCMA cells; and 3) Cy 1.5 g/m2 + 1-5 x 108 CART-BCMA cells. No pre-specified BCMA expression level was required. Results: CART-BCMA cells were manufactured and expanded in all subjects. Toxicities included cytokine release syndrome and neurotoxicity, which were grade 3-4 in 8 (32%) and 3 (12%) subjects, respectively, and reversible. One subject died at day 24 from candidemia and progressive myeloma, following treatment for severe CRS and encephalopathy. Responses (based on treated subjects) were seen in 4/9 (44%) in cohort 1, 1/5 (20%) in cohort 2, and 7/11 (64%) in cohort 3, including 5 partial, 5 very good partial, and 2 complete responses, 3 of which were ongoing at 11, 14, and 32 months. Decreased BCMA expression on residual MM cells was noted in responders; expression increased at progression in most. Responses and CART-BCMA expansion were associated with CD4:CD8 T cell ratio and frequency of CD45RO-CD27+CD8+ T cells in the pre-manufacturing leukapheresis product. Conclusion: CART-BCMA infusions with or without lymphodepleting chemotherapy are clinically active in heavily-pretreated MM patients. Trial Registration: NCT02546167. Funding: University of Pennsylvania-Novartis Alliance and NIH.

3 March 2016 in Blood
Verified
Journal Article
Open access
PDF file
JFJoseph A. Fraietta
Joseph A. Fraietta
KBKyle A. Beckwith
Kyle A. Beckwith
PPPrachi R. Patel
Prachi R. Patel
MRMarco Ruella
Marco Ruella
ZZZhaohui Zheng
Zhaohui Zheng
MMMarcela V. Maus
Marcela V. Maus
Key Points: Ibrutinib treatment of CLL enhances the generation of CAR T cells for adoptive immunotherapy. Concurrent ibrutinib therapy improves the engraftment and therapeutic efficacy of anti-CD19 CAR T cells in mouse models.

1 July 2016 in Journal of Immunological Methods
Verified
Journal Article
Closed access
FCFang Chen
Fang Chen
DTDavid Trent Teachey
David Trent Teachey
EPEdward Pequignot
Edward Pequignot
NFNoelle Frey
Noelle Frey
DPDavid Porter
David Porter
SLSimon F. Lacey
Simon F. Lacey